Skip to main content
. 2012 Jul;342(1):33–40. doi: 10.1124/jpet.112.192195

Fig. 2.

Fig. 2.

Competition assays for vemurafenib in MDCKII-MDR1 and MDCKII-Bcrp1 cells by using [3H]vinblastine (VBL) and [3H]prazosin (PRZ) as P-gp and Bcrp prototypical probe substrates, respectively. The addition of increasing concentrations of vemurafenib resulted in an increased accumulation of [3H]prazosin and [3H]vinblastine in Bcrp1 (A) and MDR1 (B) cells, respectively. The data represent mean ± S.D. (n = 3 for all data sets). *, p < 0.05; **, p < 0.01; ***, p < 0.0001.